Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population

We evaluated the real-life treatment outcomes of elderly patients with diffuse large B-cell lymphoma from an Asian population. The medical records of 192 patients aged > 60 years who had received first-line immunochemotherapy were retrospectively analyzed. Elderly patients < 75 years old tolerated standard immunochemotherapy, with acceptable survival profiles. In an Asian population, 75 years of age seems a judicious cutoff for predicting treatment outcomes.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Ja Min Byun, Jeong-Ok Lee, Beodeul Kang, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Soo-Mee Bang, Jong Seok Lee Tags: Original Study Source Type: research